Trial Profile
A randomised, double-blind, placebo-controlled, cardiovascular magnetic resonance (CMR) study to evaluate the effect of rosiglitazone on carotid atherosclerotic plaques in type 2 diabetics with vascular disease or hypertension
Status:
Active, no longer recruiting
Phase of Trial:
Phase IV
Latest Information Update: 08 Sep 2023
Price :
$35
*
At a glance
- Drugs Rosiglitazone (Primary)
- Indications Type 2 diabetes mellitus
- Focus Pharmacodynamics
- 04 Dec 2005 New trial record.